Which high‑intensity statin should be started in a 48‑year‑old African American male with a 10‑year ASCVD risk of 17.9% and newly diagnosed hypertension?

High-Intensity Statin Recommendation

Start atorvastatin 40-80 mg daily or rosuvastatin 20 mg daily for this 48-year-old African American male with 17.9% 10-year ASCVD risk. 1

Rationale for High-Intensity Statin Therapy

Your patient falls squarely into the primary prevention category requiring high-intensity statin therapy based on his 10-year ASCVD risk of 17.9%, which exceeds the ≥7.5% threshold. The 2013 ACC/AHA guidelines explicitly recommend moderate- to high-intensity statins for adults aged 40-75 years with this level of risk 1. Given his risk approaches 20%, maximal risk reduction with high-intensity therapy is reasonable and provides the greatest absolute benefit 2.

Specific Drug Choices

The evidence-based high-intensity statin options are:

• Atorvastatin 80 mg daily (first-line option)
• Rosuvastatin 20 mg daily (equally effective alternative)
• Atorvastatin 40 mg daily (acceptable if 80 mg not tolerated)

Both atorvastatin 80 mg and rosuvastatin 20 mg reduce LDL-C by approximately 50% on average and have demonstrated ASCVD event reduction in randomized controlled trials 1. While atorvastatin 40 mg also achieves roughly 50% LDL-C reduction, it was used in only one RCT as a fallback dose for patients unable to tolerate 80 mg 1.

Important Considerations for African American Patients

Asian ancestry is specifically mentioned as a safety consideration requiring potential dose adjustment 3, but no such modification is recommended for African American patients. Your patient should receive standard high-intensity dosing without ethnic-based dose reduction.

Treatment Algorithm

1. Initiate atorvastatin 80 mg or rosuvastatin 20 mg as first-line therapy
2. Obtain baseline fasting lipid panel before starting therapy 1
3. Check ALT at baseline (creatine kinase only if patient has risk factors for myopathy) 4
4. Recheck lipid panel at 4-12 weeks to assess adherence and response 4
5. Target ≥50% LDL-C reduction (though not a strict goal, this indicates adequate response) 1
6. If atorvastatin 80 mg causes side effects, consider switching to rosuvastatin 20 mg or downtitrating to atorvastatin 40 mg 1

Common Pitfalls to Avoid

Do not start with moderate-intensity therapy in this patient. With a 10-year risk of 17.9%, he derives substantially greater absolute benefit from high-intensity therapy compared to moderate-intensity 2. The higher the baseline risk, the greater the benefit from maximal LDL-C lowering.

Do not delay statin initiation while addressing his newly diagnosed hypertension. Both conditions should be treated concurrently, as they represent independent cardiovascular risk factors.

Monitor for statin-associated muscle symptoms at each visit, but do not routinely check creatine kinase unless symptoms develop 4. The risk of myopathy is extremely low (0.01 excess cases per 100 patients) 4.

Safety Monitoring

• Baseline ALT measurement required
• Repeat ALT only if symptoms of hepatotoxicity develop (not routine monitoring) 4
• Ask about muscle symptoms at each visit
• The modest increase in diabetes risk (approximately 0.3 excess cases per 100 patients/year with high-intensity statins) is far outweighed by ASCVD risk reduction at his risk level 4

If LDL-C remains ≥100 mg/dL on maximally tolerated statin after 4-12 weeks, reassess adherence to medications and lifestyle modifications before considering additional therapy 5.